Scarica l'app Stockscreener
0.7496
0.74%
0.0055
Dopo l'orario di chiusura:
.75
0.0004
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Maxcyte Inc Borsa (MXCT) Ultime notizie
MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI
MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - msn.com
Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - Stock Titan
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - Stock Titan
RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - msn.com
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - GuruFocus
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds By Investing.com - Investing.com Australia
Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat
Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com
Stifel cuts MaxCyte stock price target on 2026 revenue guidance By Investing.com - Investing.com Australia
MaxCyte 2025 Financial Results Review - AlphaStreet
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
MaxCyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript - insidermonkey.com
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... By GuruFocus - Investing.com Canada
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts - Investing.com
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts By Investing.com - Investing.com Australia
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - TipRanks
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):